This patent application belongs to
the main family of patents of BiondVax for vaccination against
influenza in humans, and specifically vaccines that confer long-lasting
protection against multiple and differing flu strains. The Israeli
Intellectual Property Office accepted BiondVax's claims for M-001
(BiondVax's universal flu vaccine) and similar polypeptides.

Patent protection has already been granted in a number of other countries, namely the United States, Europe, Japan, Hong Kong, Australia, China, Russia, Mexico and Korea.

Ron Babecoff, CEO of BiondVax
said "We are very pleased that the Israeli patent authorities accepted
the uniqueness of our universal flu vaccine solution, approving this
main patent of BiondVax. Our solution is patent protected in many of the
countries where we believe our vaccine will provide increased
protection to the local population from flu, including multiple European
countries, in the United States and in the Far East."

About BiondVax Pharmaceuticals Ltd

BiondVax is an innovative
biopharmaceutical company developing a universal flu vaccine, designed
to provide multi-season and multi-strain protection against most human
influenza virus strains, including both seasonal and pandemic flu
strains.

BiondVax's technology utilizes a
unique, proprietary combination of conserved and common peptides from
influenza virus proteins to activate both arms of the immune system for a
cross-protecting and long-lasting effect.

Forward Looking Statements

This press release contains
forward-looking statements within the meaning of the Private Litigation
Reform Act of 1995. Words such as "expect," "believe," "intend," "plan,"
"continue," "may," "will," "anticipate," and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements involve certain risks and uncertainties reflect the
management's current views with respect to certain current and future
events and are subject to various risks, uncertainties and assumptions
that could cause the results to differ materially from those expected by
the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties
include, but are not limited to, the risk that drug development
involves a lengthy and expensive process with uncertain outcome,BiondVax's ability to continue obtaining and maintaining intellectual property protection for our Universal Flu Vaccine, risks inherent inthe
development and commercialization of potential products, dependence
upon collaborators, and adequacy of capital resources for product
development and commercialization. The risks, uncertainties and
assumptions referred to above are discussed in detail in our reports
filed with the Securities and Exchange Commission, including our
Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes no obligation to update or revise any forward-looking statements.

DISCLOSURE:
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Cloudera offers enterprises a new data platform built on the Apache
Hadoop open-source software package. Hadoop is a data-management
platform that can consolidate data in a single repository for
comprehensive…